The War’s Most Dangerous Shortage Isn’t Oil

RIYADH — Seventeen days into the Iran war, the global conversation remains fixated on oil prices, missile trajectories, and the geopolitics of the Strait of Hormuz. That fixation is dangerously misplaced. The most consequential shortage now threatening Saudi Arabia’s 35 million residents is not crude oil — which can be rerouted through the Yanbu terminal on the Red Sea — but pharmaceutical drugs, which cannot. The Kingdom imports 64 percent of its medicines, the overwhelming majority through supply chains that pass through or near the Persian Gulf. Those routes are now severed or degraded. Hospitals that serve millions depend on a workforce where nearly three-quarters of physicians hold foreign passports, and many are calculating whether to stay. The collision of pharmaceutical import dependency, healthcare workforce fragility, and wartime logistics disruption constitutes an emerging crisis that no amount of strategic petroleum reserves can solve. Saudi Arabia is discovering that its most dangerous vulnerability was never energy. It was health.

How Dependent Is Saudi Arabia on Imported Medicine?

Saudi Arabia’s pharmaceutical import bill reached $7.78 billion in 2023, according to Trading Economics data, making the Kingdom one of the largest medicine importers in the Middle East. That figure represents not a luxury but a lifeline. The Kingdom’s roughly 40 pharmaceutical factories produce only 36 percent of the drugs its population consumes, according to research published in the National Institutes of Health’s PubMed Central database. The remaining 64 percent arrives by air, sea, and land from manufacturers scattered across Europe, India, the United States, and East Asia.

The dependency is not evenly distributed across drug categories. Generic medications for common conditions — hypertension, diabetes, respiratory infections — have some domestic manufacturing capacity. But specialized biologics, oncology drugs, immunosuppressants, and the full range of anesthetics and surgical pharmaceuticals remain almost entirely imported. Insulin, the drug that keeps an estimated 4.3 million Saudi diabetics alive, was until recently 100 percent imported. The Kingdom inaugurated its first local insulin manufacturing facility in late 2025, a milestone that seemed like a planning triumph six months ago and now looks like barely a first step.

The import dependency extends beyond finished pharmaceutical products to the raw materials that Saudi factories need to produce even their 36 percent share. Active pharmaceutical ingredients — the chemical compounds that give drugs their therapeutic effect — are manufactured overwhelmingly in India and China. Indian API exports transit through ports and air hubs that are now disrupted. Even factories physically located in Saudi Arabia cannot produce medicines if they cannot source the inputs. Domestic production capacity on paper and actual production capability during wartime are proving to be very different numbers.

The National Unified Procurement Company, known as NUPCO, serves as the central purchasing arm for the Saudi healthcare system. It supports more than 300 hospitals and 2,500 clinics across the Kingdom, and in 2025 secured $667 million in financing to expand its procurement capabilities, according to Arab News. NUPCO’s reach is impressive — covering approximately 97 percent of public healthcare facilities — but its model was built for peacetime global supply chains, not for wartime scarcity.

The raw numbers tell a story of structural vulnerability. A nation of 35 million people, including 13 million expatriates trapped in the Kingdom, depends on a pharmaceutical pipeline that was never stress-tested for the scenario now unfolding. Strategic stockpiles exist, but their depth is classified. Industry estimates suggest 30 to 90 days of supply for essential medications, a window that narrows rapidly when demand spikes and resupply routes collapse simultaneously.

The Hormuz Bottleneck Reaches the Pharmacy

The Strait of Hormuz is discussed almost exclusively in the context of oil. That framing misses the strait’s role as a chokepoint for virtually every category of goods flowing into the Persian Gulf states. Pharmaceutical raw materials from India, finished drugs from European manufacturers transiting through Dubai, and medical devices from East Asian suppliers all flow through or near Hormuz. The strait’s effective closure has not merely disrupted oil markets. It has severed the pharmaceutical artery that feeds hospitals from Riyadh to Dammam.

The disruption operates on multiple levels. Direct maritime shipments of bulk pharmaceutical ingredients through the Gulf are halted. Air cargo, which carried the most time-sensitive medications, depended heavily on Dubai International Airport and Abu Dhabi’s logistics hubs — both now closed to commercial operations as the UAE absorbs the consequences of regional conflict. Even overland routes from Jordan and Egypt face delays as border security tightens and commercial trucking companies reassess risk.

Pharmaceutical companies have begun emergency rerouting. According to PharmExec reporting, major suppliers are redirecting shipments through Jeddah’s King Abdulaziz International Airport, Riyadh’s King Khalid International Airport, and Istanbul’s cargo terminals. But rerouting is not seamless. Cold-chain medications — vaccines, biologics, certain insulins — require unbroken refrigeration from factory to pharmacy. Every additional transit point, every unplanned layover, every warehouse transfer introduces risk of temperature excursion and product spoilage.

The situation mirrors what is already happening with the Hormuz blockade cutting off metals and industrial supplies. Pharmaceuticals are simply the most immediately life-threatening category in a cascade of non-oil import disruptions that defense planners consistently underweighted. Hormuz was always more than an oil chokepoint. It was a civilization chokepoint.

For the eastern provinces of Saudi Arabia — home to major population centers including Dammam, Dhahran, and Al-Khobar — the disruption is most acute. These cities sit closest to the conflict zone, their hospitals serve populations that include significant numbers of oil-sector workers, and their supply lines ran most directly through Gulf maritime and air routes. Pharmacies in Dammam are already reporting shortages of common antibiotics, a development that would have been unthinkable a month ago.

Where Do Saudi Arabia’s Doctors and Nurses Come From?

Saudi Arabia’s healthcare system employs 545,574 workers according to 2023 data from the Saudi General Authority for Statistics. That workforce breaks down into approximately 325,000 nurses, 153,000 physicians, and 59,000 pharmacists, with the remainder distributed across allied health professions. The numbers appear robust. The composition tells a different story.

Seventy-three percent of physicians practicing in Saudi Arabia are foreign-born, according to research published in PubMed Central. The figure for nurses is approximately 62 percent, per data compiled by Springer Nature. These professionals come overwhelmingly from the Philippines, India, Egypt, Pakistan, Jordan, and Sudan. Many have spent decades in the Kingdom. They are not transient workers. They are the backbone of a healthcare system that could not function without them.

The dependency on expatriate medical professionals is not an oversight. It is the product of a deliberate development model that prioritized rapid healthcare infrastructure expansion over the slower process of training domestic medical professionals. Saudi Arabia built hospitals faster than it could fill them with Saudi doctors. The result is a system where the physical infrastructure — 499 hospitals, modern equipment, world-class facilities — belongs to the Kingdom, but the human capital that operates it holds passports from a dozen other nations.

This model worked brilliantly in peacetime. It attracted talented professionals with competitive salaries, modern facilities, and tax-free income. It allowed Saudi Arabia to achieve healthcare outcomes that improved dramatically over three decades. But the model contained an assumption so fundamental it was invisible: that the professionals would stay.

What Happens When Healthcare Workers Leave During a War?

The calculus facing expatriate healthcare workers in Saudi Arabia is brutally simple. They came to work, not to endure a war. Their families — many residing in the Kingdom — are now living under missile threat. The strike on a residential area in Al-Kharj that killed two and wounded twelve, reported by Al Jazeera, demonstrated that civilian areas are not immune. For a Filipino nurse in Riyadh or an Egyptian physician in Jeddah, the question is no longer whether to renew a contract. It is whether to get on the next available flight out.

Embassy evacuation advisories have been issued by multiple nations. The Philippines, India, and Pakistan — the three largest sources of healthcare workers in Saudi Arabia — have all activated repatriation protocols. Not every expatriate will leave. Many have deep roots, financial obligations, and professional commitments. But even a 10 to 15 percent departure rate among healthcare professionals would cripple the system. A 25 percent departure rate would constitute a crisis on par with the pharmaceutical shortage itself.

The social contract between the Saudi state and its population has always included an implicit promise of world-class healthcare. That promise was built on the labor of foreign professionals. The war is now testing whether the contract can survive the departure of the people who actually delivered on it.

Historical precedent is not encouraging. During the Gulf War of 1990-1991, significant numbers of expatriate workers — including healthcare professionals — departed Saudi Arabia. The difference today is the scale. The healthcare system is vastly larger, more complex, and more dependent on specialized expatriate labor than it was 35 years ago. A surgeon who leaves cannot be replaced by a Saudization initiative next quarter. Training a specialist takes a decade.

The Ministry of Health has reportedly offered retention bonuses and expedited residency benefits to healthcare workers who commit to staying. These measures may slow the bleeding. They cannot stop it. When sirens sound and missiles fall, no bonus is large enough to override the instinct to protect one’s family.

The departure pattern is not random. It follows a predictable hierarchy of specialization and replaceability. General practitioners and junior nurses — positions with the shortest training timelines — are the most likely to leave because they are the most confident of finding equivalent employment elsewhere. But the most devastating departures are among senior specialists: anesthesiologists, trauma surgeons, oncologists, and intensive care physicians whose skills took 10 to 15 years to develop and cannot be replaced at any price in a wartime labor market. Each specialist who boards a repatriation flight takes a decade of training with them.

The geographic distribution of departures compounds the problem. Healthcare workers stationed in the eastern provinces — closer to the conflict zone and to potential missile impact areas — are leaving at higher rates than those in Jeddah or Medina on the western coast. This creates a paradox: the hospitals most likely to receive wartime casualties are also the hospitals most likely to lose the staff needed to treat them. The Saudi Red Crescent Authority and military medical services can partially fill the gap, but their capacity is designed for surge events, not sustained operations.

Can Saudi Hospitals Handle Wartime Casualties and Chronic Patients?

Saudi Arabia operates 499 hospitals with a bed density of 2.26 beds per 1,000 people, according to the Saudi General Authority for Statistics. That figure sits below the G20 average of 2.85 beds per 1,000 and well below countries with robust wartime medical preparedness like Germany (8.0) and Japan (13.0). In peacetime, 2.26 beds per thousand is manageable. In wartime, when casualties compete with chronic disease patients for the same beds, it becomes a triage nightmare.

The challenge is not merely bed count. It is the simultaneous management of two entirely different patient populations with competing needs. Wartime casualties — blast injuries, burns, shrapnel wounds, crush injuries — require emergency surgical capacity, intensive care beds, blood products, and specific pharmaceuticals including anesthetics, analgesics, and antibiotics. Chronic disease patients — the Kingdom’s millions living with diabetes, cardiovascular disease, kidney failure requiring dialysis, and cancer patients mid-chemotherapy — require ongoing access to medications and regular clinical contact. Both populations surge during wartime. Neither can be neglected without fatal consequences.

A study published in the Saudi Medical Journal found that 92.3 percent of Saudi hospitals have disaster preparedness plans on paper. The same research identified significant weaknesses in actual training and drill execution. Having a plan and executing a plan under the chaos of missile strikes, supply shortages, and staff departures are fundamentally different activities. Paper preparedness may be the most dangerous form of false confidence in the Kingdom’s healthcare system.

The diabetes burden alone illustrates the scale of the chronic care challenge. Saudi Arabia has one of the highest diabetes prevalence rates globally. An estimated 4.3 million Saudi residents are diabetic, and many require daily insulin. If insulin supply is disrupted for even two weeks — a plausible scenario given current import route degradation — hospitals will face a wave of diabetic ketoacidosis cases that could overwhelm emergency departments independent of any military casualties.

Dialysis patients face an even more acute timeline. Kidney failure patients require dialysis sessions multiple times per week. Missing sessions leads to toxin buildup, fluid overload, and death within days to weeks. Saudi Arabia has approximately 20,000 dialysis patients. Each session requires purified water, specialized consumables, and functioning machines. The desalination infrastructure that delivers 70 percent of the Kingdom’s water is itself under wartime stress, adding another vulnerability layer to dialysis provision.

The Dubai Hub That Fed the World’s Hospitals Has Gone Dark

The World Health Organization operated a major humanitarian logistics hub in Dubai — the International Humanitarian City — that served as the primary staging point for medical supplies destined for the Middle East, East Africa, and South Asia. That hub is now paralyzed. According to Health Policy Watch reporting, approximately $18 million worth of medical supplies are stuck in the facility, with more than 50 emergency procurement requests affecting an estimated 1.5 million people across the region left unfulfilled.

Dubai’s role in global pharmaceutical logistics extended far beyond the WHO hub. Dubai International Airport was the world’s busiest airport for international passenger traffic and a critical node for pharmaceutical air cargo. Abu Dhabi and Doha served complementary roles. The closure of all three airports to normal commercial operations, confirmed by Direct Relief, has eliminated the Gulf’s function as a pharmaceutical transshipment center virtually overnight.

The implications extend beyond Saudi Arabia. Yemen, already enduring the world’s worst humanitarian crisis, depended on supplies flowing through Dubai. East African nations received WHO-procured medicines through the same hub. The cascading effect of the Dubai shutdown is creating pharmaceutical deserts across an arc stretching from the Horn of Africa to Central Asia. Saudi Arabia, with its wealth and alternative port access through the Red Sea, is better positioned than most affected nations. But “better positioned than Yemen” is not a standard any Saudi policymaker should find reassuring.

The Red Sea port of Jeddah and the industrial port of Yanbu are now carrying burdens they were never designed to bear. Jeddah’s King Abdulaziz International Airport has become the de facto primary import gateway for pharmaceuticals entering the Kingdom. Port facilities at Jeddah Islamic Port are handling redirected maritime cargo. The infrastructure exists, but the logistics chains — customs clearance protocols, cold-chain facilities, last-mile distribution networks — were optimized for the eastern seaboard. Rebuilding them on the western side of the Kingdom takes time that patients do not have.

The war exposed a fragility that no amount of GDP could disguise. Saudi Arabia built a first-world healthcare system on a supply chain that assumed permanent peace in the most volatile region on earth. That assumption has now been tested, and it failed in seventeen days.

— Senior healthcare logistics consultant, speaking on condition of anonymity

Pharmaceutical rerouting also introduces regulatory complications. Saudi Arabia’s Food and Drug Authority maintains strict import controls on medications — controls designed to prevent counterfeit and substandard drugs from entering the market. Under wartime pressure, the temptation to relax these controls is immense. But relaxing pharmaceutical import standards carries its own risks. Counterfeit medications kill. The balance between speed and safety in emergency pharmaceutical procurement is one of the most consequential decisions Saudi regulators now face.

The cold-chain problem deserves particular emphasis. Vaccines, many biologics, insulin formulations, and certain antibiotics require continuous refrigeration at specific temperatures. The Gulf’s pharmaceutical cold-chain infrastructure was among the most sophisticated in the developing world, centered on purpose-built facilities in Dubai, Abu Dhabi, and Dammam. With the eastern facilities operating under wartime constraints and the Dubai hub shut down, the Kingdom is attempting to route temperature-sensitive medications through Jeddah’s airport cargo facilities — facilities that handle warm-climate agricultural imports, not pharmaceutical-grade cold storage at scale. Every hour of temperature deviation can render an entire shipment of biologics worthless. The waste rate for rerouted cold-chain pharmaceuticals is estimated to be running between 15 and 25 percent, a figure that would be scandalous in peacetime and is catastrophic when supply is already constrained.

The Wartime Pharmaceutical Resilience Index

Assessing a nation’s pharmaceutical preparedness for conflict requires evaluating multiple interconnected dimensions. A single metric — import dependency, stockpile depth, or manufacturing capacity — tells an incomplete story. The following Wartime Pharmaceutical Resilience Index evaluates Saudi Arabia across six critical dimensions, each rated on a scale from LOW to HIGH based on available data and wartime performance in the first seventeen days of conflict.

The index reveals a pattern common to wealthy Gulf states: exceptional investment in physical and digital infrastructure, combined with critical dependency on imported human capital and imported physical goods. Saudi Arabia scores HIGH only on digital health infrastructure — the NUPCO system that connects 97 percent of public healthcare facilities to a centralized procurement platform. That system is a genuine achievement. It means the Kingdom knows exactly where shortages are developing in real time. What it cannot do is fill those shortages when the supply chain feeding it has been disrupted.

The LOW rating on import route diversity is the most immediately dangerous finding. Saudi Arabia’s pharmaceutical imports historically flowed through a limited number of channels, predominantly Gulf-facing. The assumption that Hormuz would remain open was baked into the entire logistics architecture. Diversifying to Red Sea routes is underway but represents a wartime improvisation, not a pre-planned contingency. The difference matters when measured in patient outcomes.

Healthcare workforce stability rated LOW represents the slow-motion crisis. Unlike a pharmaceutical shipment that arrives or doesn’t, workforce departure happens incrementally. Each departing physician or nurse increases the burden on those who remain, accelerating burnout and creating a negative feedback loop. The first departures have already begun. The question is whether the rate remains manageable or reaches a tipping point.

The Mental Health Epidemic Nobody Is Counting

The casualties that arrive at hospital emergency departments are counted, photographed, and reported. The casualties that will arrive at psychiatric clinics over the coming months and years are invisible, uncounted, and largely unplanned for. Seventeen days of air raid sirens, shelter-in-place orders, social media footage of missile interceptions, and the ambient terror of living within range of ballistic weapons are producing a population-wide psychological toll that Saudi Arabia’s mental health infrastructure is not remotely prepared to address.

Research published in SAGE Journals documents post-traumatic stress disorder prevalence rates of 20 to 30 percent in conflict-affected populations across the Middle East and North Africa region. That range, applied to Saudi Arabia’s population of 35 million, implies a potential PTSD burden of 7 to 10.5 million people. Even assuming the conflict remains limited and Saudi civilian exposure is less intense than in directly invaded territories, a conservative PTSD prevalence of 5 to 10 percent would still represent 1.75 to 3.5 million people requiring mental health support.

Saudi Arabia’s mental health infrastructure was already strained before the war. The Kingdom has made significant investments under Vision 2030 in expanding mental health services and reducing stigma, but the ratio of psychiatrists and psychologists to population remains well below international benchmarks. Adding wartime psychological trauma to pre-existing demand creates a gap that will take years to close.

Children are disproportionately affected. Pediatric psychological research consistently shows that children exposed to conflict — even indirectly through sirens, parental anxiety, disrupted routines, and media exposure — develop anxiety disorders, sleep disturbances, and behavioral changes at rates significantly above baseline. Saudi Arabia’s young population, with a median age of approximately 31, includes millions of children experiencing their first exposure to the sounds and fears of war. The long-term developmental consequences of this exposure are not speculative. They are documented across every conflict zone studied in the past half-century.

The mental health crisis intersects with the healthcare workforce crisis in a particularly vicious way. Many of the Kingdom’s psychiatric professionals are themselves expatriates. If they leave, the remaining system must absorb both the general patient population and the war-traumatized population with fewer providers. Mental health is also the domain most likely to be deprioritized during acute wartime — triaged away in favor of surgical and emergency care. The result is a deferred crisis that will present its bill after the final ceasefire.

The Al-Kharj attack that killed two civilians and wounded twelve in a residential area, as reported by Al Jazeera, had psychological effects extending far beyond the physical blast radius. Every resident of Al-Kharj — and every Saudi who watched the footage — internalized a new reality: residential neighborhoods are targets. The psychological impact of that single strike, measured in anxiety, insomnia, and hypervigilance across a national population, dwarfs its physical casualty count by orders of magnitude. The civilian shelter infrastructure that could mitigate some of this psychological burden remains inadequate.

Can Vision 2030’s Pharmaceutical Push Save Saudi Arabia in Time?

Crown Prince Mohammed bin Salman‘s Vision 2030 program identified pharmaceutical localization as a strategic priority years before the current conflict. The target, according to Global Business Outlook reporting, was to localize 40 percent of drug production domestically — a goal that acknowledged the Kingdom’s import vulnerability without fully anticipating the scenario that would test it. The war has transformed pharmaceutical localization from a medium-term industrial policy objective into an immediate survival question.

Progress before the war was real but incremental. The Kingdom’s 40 pharmaceutical factories expanded capacity. The first domestic insulin manufacturing facility came online. NUPCO’s 2026 procurement tenders were restructured to require that only locally manufactured products qualify for certain categories, with a 15 percent “Made in Saudi” scoring advantage built into the evaluation criteria, according to Saudi Healthcare Consulting. These were sound policies for a five-year transition. They are insufficient for a five-week crisis.

The structural limitation is that pharmaceutical manufacturing is among the most complex, regulated, and capital-intensive industries on earth. Building a factory is the easy part. Achieving regulatory approval, establishing quality systems that meet international pharmacopoeia standards, securing active pharmaceutical ingredient supply chains, and training the specialized workforce to operate production lines — each step takes years. Saudi Arabia cannot manufacture its way out of the current crisis. It can only build the foundation to prevent the next one.

What Vision 2030 did provide, and what is proving valuable now, is institutional infrastructure. NUPCO’s centralized procurement system allows the Ministry of Health to identify shortages in real time and redirect available supplies to the facilities with the most critical need. The digital health infrastructure — electronic medical records, telemedicine capabilities, centralized pharmacy management systems — enables a degree of demand management and resource allocation that would be impossible in a less digitized system.

The war is also accelerating policy decisions that peacetime politics would have delayed for years. Emergency regulatory pathways for pharmaceutical imports are being created. Bilateral agreements with pharmaceutical manufacturers in Turkey, Egypt, and India for direct-to-Jeddah shipments are being negotiated under wartime urgency. The Kingdom’s sovereign wealth fund is reportedly exploring emergency acquisitions of pharmaceutical manufacturing capacity — buying factories rather than waiting to build them. Crisis, as it often does, is compressing a decade of policy evolution into weeks.

The question is whether any of these accelerated measures can produce results within the 30-to-90-day window that existing stockpiles are estimated to cover. For generic medications with existing domestic capacity, the answer is cautiously optimistic. For biologics, oncology drugs, and specialized surgical pharmaceuticals, the answer is almost certainly no. The gap between what Saudi Arabia can produce and what its population needs will persist through the duration of the conflict and likely for months beyond it.

The private sector is responding with its own wartime adaptations. Saudi pharmaceutical distributors are negotiating direct agreements with Turkish and Egyptian manufacturers, bypassing the traditional European and Indian supply chains entirely. These emergency contracts sacrifice cost efficiency for supply certainty — drugs procured through wartime bilateral channels cost 30 to 50 percent more than pre-war procurement prices. But when the alternative is empty pharmacy shelves, cost becomes secondary. The Kingdom’s deep financial reserves, funded by decades of oil revenue, provide a buffer that poorer nations in the same pharmaceutical crisis simply do not have. Money cannot solve every supply chain problem, but it can solve some of them faster.

What Other Wartime Healthcare Crises Teach Saudi Arabia

Ukraine’s experience since February 2022 offers the most relevant recent comparison, though the differences are as instructive as the similarities. Ukraine entered its war with a largely domestic healthcare workforce — Ukrainian doctors treating Ukrainian patients. The workforce did not have an expatriate departure risk. What Ukraine faced instead was physical destruction of healthcare infrastructure, with hundreds of hospitals and clinics damaged or destroyed by Russian strikes. Saudi Arabia’s infrastructure remains largely intact. Its vulnerability is the supply chain and workforce, not the buildings.

Ukraine also benefited from geographic proximity to the European Union, which provided an immediate alternative supply corridor for pharmaceuticals. Polish, Romanian, and Slovak border crossings became pharmaceutical lifelines within days. Saudi Arabia’s geographic alternatives — the Red Sea coast — are more distant from major pharmaceutical manufacturing centers and require more complex logistics to activate. The EU does not border Saudi Arabia. There is no Polish border crossing equivalent for Riyadh.

Yemen’s healthcare catastrophe since 2015 provides a darker precedent. The Saudi-led coalition’s own blockade of Yemeni ports contributed to a pharmaceutical crisis that killed more Yemenis than direct military action. Hospitals ran out of anesthetics. Dialysis patients died. Cancer patients went untreated. The bitter irony that Saudi Arabia may now experience a version of the pharmaceutical deprivation its own military operations inflicted on Yemen is not lost on regional observers. The mechanisms are different — Hormuz closure versus deliberate blockade — but the downstream effects on hospital pharmacies are functionally identical.

The COVID-19 pandemic also provides relevant lessons, though the analogy is imperfect. During the pandemic, Saudi Arabia experienced supply chain disruption for personal protective equipment and certain pharmaceuticals. The response — centralized procurement through NUPCO, emergency regulatory pathways, and strategic stockpile deployment — provides a template for the current crisis. The critical difference is that the pandemic did not simultaneously threaten the physical safety of healthcare workers or destroy the logistics infrastructure through which supplies moved. The current crisis combines supply disruption with workforce instability and physical danger in a way the pandemic never did.

The common thread across all wartime healthcare crises is that systems optimized for peacetime efficiency fail under wartime stress in predictable ways. Just-in-time pharmaceutical supply chains, which minimize warehouse costs and reduce waste, become just-in-time-to-run-out chains when resupply is interrupted. Expatriate-dependent workforces, which maximize flexibility and access to global talent, become flight risks when the operating environment becomes dangerous. Centralized hospital systems, which provide economies of scale, become single points of failure when one supply chain serves all facilities. Saudi Arabia’s healthcare system embodies every one of these peacetime optimization traps.

A healthcare system is only as resilient as its weakest supply line. Saudi Arabia’s hospitals are world-class. The question was never whether the buildings could handle a crisis. It was whether the people and products inside them would still be there when the crisis arrived.

— Regional healthcare policy analyst

The lesson from Ukraine, Yemen, and the pandemic is identical: pharmaceutical resilience must be built before the crisis, not during it. Stockpiles must be deeper than financial analysts recommend. Domestic manufacturing must exceed what peacetime economics justify. Workforce nationalization must proceed faster than the labor market prefers. Every one of these measures costs money and reduces short-term efficiency. Every one of them pays for itself the moment the first missile flies. The food supply chains already buckling under Hormuz closure tell the same story in a different sector: resilience and efficiency are opposing forces, and Saudi Arabia chose efficiency.

The broader lesson for the Gulf Cooperation Council states — Kuwait, Bahrain, Qatar, the UAE, and Oman — is that pharmaceutical dependency is a shared structural vulnerability. Every GCC nation imports the vast majority of its medicines. Every GCC nation depends heavily on expatriate healthcare workers. The war is testing Saudi Arabia first, but the systemic fragility it is exposing belongs to the entire Gulf development model. What happens in Saudi hospitals over the next 90 days will determine pharmaceutical policy across the region for a generation.

As the construction and megaproject pipeline ground to a halt, the resources freed could theoretically be redirected toward emergency healthcare logistics. But reallocating economic resources during wartime is not as simple as redirecting budget lines. The specialized skills, equipment, and supply chains needed for pharmaceutical manufacturing and medical logistics are not fungible with those used for construction. Saudi Arabia cannot build its way to pharmaceutical security with concrete and steel. It needs active pharmaceutical ingredients, cold-chain logistics, and trained pharmacists — none of which can be sourced from a megaproject budget.

Frequently Asked Questions

How much medicine does Saudi Arabia import?

Saudi Arabia imported $7.78 billion worth of pharmaceuticals in 2023. Domestic manufacturing covers only 36 percent of the Kingdom’s drug consumption, meaning nearly two-thirds of all medications used in Saudi hospitals and pharmacies arrive from foreign manufacturers, primarily in Europe, India, and East Asia. The 40 local factories cannot close this gap in the near term.

Why is the Strait of Hormuz important for pharmaceutical supplies?

The Strait of Hormuz served as the primary maritime and air logistics corridor for pharmaceuticals entering the Gulf region. Dubai, Abu Dhabi, and Doha airports — all now closed to commercial traffic — were major pharmaceutical cargo hubs. The WHO’s Dubai humanitarian logistics hub, which staged medical supplies for the entire region, has $18 million in supplies stuck and more than 50 emergency requests unfulfilled.

What percentage of Saudi doctors are foreign nationals?

Approximately 73 percent of physicians practicing in Saudi Arabia are foreign-born, according to published medical research. The figure for nurses is approximately 62 percent. The Kingdom’s total healthcare workforce of 545,574 includes 153,000 physicians and 325,000 nurses, the majority of whom hold foreign passports and face personal safety calculations about whether to remain during the conflict.

Can Saudi Arabia manufacture its own medicines during the war?

Not at sufficient scale. The Kingdom’s 40 pharmaceutical factories produce some generic medications domestically, and a new insulin manufacturing facility recently began operations. However, biologics, oncology drugs, immunosuppressants, and most specialized surgical pharmaceuticals remain entirely import-dependent. Vision 2030 set a target of 40 percent domestic production, but achieving that goal requires years of regulatory approval, quality system development, and workforce training.

How many hospital beds does Saudi Arabia have?

Saudi Arabia operates 499 hospitals with a bed density of 2.26 beds per 1,000 people, according to the Saudi General Authority for Statistics. That rate falls below the G20 average of 2.85 beds per thousand. During wartime, when military casualties compete with chronic disease patients for the same beds, this below-average capacity becomes a critical constraint on the healthcare system’s ability to respond.

What is NUPCO and what role does it play?

The National Unified Procurement Company, or NUPCO, is Saudi Arabia’s centralized pharmaceutical purchasing organization. It supports more than 300 hospitals and 2,500 clinics, covering 97 percent of public healthcare facilities. NUPCO secured $667 million in financing in 2025 to expand operations. Its digital infrastructure enables real-time shortage tracking, but the system was designed for peacetime supply chains now under severe wartime stress.

What mental health impact is the war having on Saudi civilians?

Research from conflict zones across the Middle East and North Africa documents PTSD prevalence rates of 20 to 30 percent in affected populations. Even a conservative estimate of 5 to 10 percent applied to Saudi Arabia’s population implies 1.75 to 3.5 million people requiring mental health support. Children are disproportionately affected, and the Kingdom’s pre-war mental health infrastructure was already below international staffing benchmarks. For the latest updates, see Iran War coverage.